Astria Therapeutics, Inc.ATXSNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-6.92%
↓ 189% below average
Average (39q)
7.74%
Historical baseline
Range
High:101.42%
Low:-54.87%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -6.92% |
| Q2 2025 | -6.63% |
| Q1 2025 | 37.82% |
| Q4 2024 | -1.70% |
| Q3 2024 | -0.96% |
| Q2 2024 | 31.69% |
| Q1 2024 | -41.47% |
| Q4 2023 | 101.42% |
| Q3 2023 | 46.75% |
| Q2 2023 | 13.15% |
| Q1 2023 | -16.24% |
| Q4 2022 | 24.59% |
| Q3 2022 | 16.34% |
| Q2 2022 | -36.12% |
| Q1 2022 | 81.94% |
| Q4 2021 | 50.29% |
| Q3 2021 | 8.91% |
| Q2 2021 | 34.13% |
| Q1 2021 | -54.87% |
| Q4 2020 | -26.40% |
| Q3 2020 | 15.64% |
| Q2 2020 | 27.62% |
| Q1 2020 | 24.07% |
| Q4 2019 | -9.24% |
| Q3 2019 | -8.97% |
| Q2 2019 | 22.94% |
| Q1 2019 | 14.70% |
| Q4 2018 | -6.11% |
| Q3 2018 | -8.07% |
| Q2 2018 | -19.21% |
| Q1 2018 | 31.54% |
| Q4 2017 | -16.48% |
| Q3 2017 | 5.69% |
| Q2 2017 | -16.28% |
| Q1 2017 | -13.77% |
| Q4 2016 | 5.46% |
| Q3 2016 | -12.94% |
| Q2 2016 | 5.94% |
| Q1 2016 | -3.51% |
| Q4 2015 | 14.74% |